Table 2. Allogeneic anti—third-party... | American Society of Hematology

Table 2.

Allogeneic anti—third-party CTLs do not exhibit reactivity against AML

	AML	AML + anti—third-party CTL
Patient no.	% CD33/13⁺	% CD33/13⁺	% AML eradication^*
1	18.1	19.1	−0.05†
2	44	53	−20
3	41.7	39.58	0.05

	AML	AML + anti—third-party CTL
Patient no.	% CD33/13⁺	% CD33/13⁺	% AML eradication^*
1	18.1	19.1	−0.05†
2	44	53	−20
3	41.7	39.58	0.05

Three mice were used in each group.

This value was calculated as follows: [% untreated − % treated/untreated] × 100.

Pf > .4.